Simcere Pharmaceutical Group Limited (Simcere Pharma) has filed a Next Day Disclosure Return detailing its latest on-market share repurchase under the Hong Kong Stock Exchange’s Main Board Rule 13.25A.

On 9 September 2026, the company bought back 929,000 ordinary shares on the Exchange at prices ranging from HKD 11.48 to HKD 11.554 per share, for a total consideration of HKD 10.70 million. The volume-weighted average repurchase price was HKD 11.5213 per share.

Including this transaction, Simcere has repurchased 1.98 million shares since its current mandate was granted on 12 June 2026, equivalent to 0.77 % of the 256.82 million shares authorised for repurchase and 0.08 % of the company’s 2.57 billion issued shares (excluding treasury shares) outstanding as at the mandate date.

The repurchased shares—1.05 million on 2 September and 0.93 million on 9 September—have not yet been cancelled. Consequently, Simcere’s issued share capital remains at 2.57 billion shares, with no treasury shares reported as at 9 September 2026.

Under Main Board Rule 10.06(3)(a), the company is subject to a moratorium on issuing new shares or selling treasury shares until 9 October 2026.